Friday, November 16, 2018 3:15:45 PM
Love this. It just proves how unqualified/unethical Adam F is to be a "Biotech Journalist".
His Tweets to Rago below just about proves his ineptness.
"Dcvax is not a 2nd generation dendritic cell vaccine. It’s way older. Also, it doesn’t target neoantigens, certainly not as currently defined.
Hi Carlo — DCVax is old. It belongs to the first class of “dumb” cancer vaccines, all of which failed (Provenge excepted*). If neoantigens are your thing, I suggest the new crop of cancer vaccine startups. Look at "How many of the previous cancer vaccine trials failed because they did not look at the hazard ratio beyond the median?
He even references Provenge to make his point which actually makes Rago's point if he knew anything about the biology he claims to be an expert on. Provenge showed neoantigens years ago.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876693/
we evaluated humoral antigen spread after sipuleucel-T treatment in patients with metastatic castration-resistant prostate cancer. In addition, we validated a subset of these serum immunoglobulin G responses in patients from the ProACT (Prostate Active Cellular Therapy) study. We presented our results at the 2014 American Society of Clinical Oncology Genitourinary Cancers Symposium. We found that 38% of the patients given sipuleucel-T made antibodies to ERAS, 27% made antibodies to KLK2, and 27% made antibodies to KRAS. It was very clear that this antigen spread occurred only in the patients who got vaccinated—it did not occur in any of the control patients.
So in 2014 they stated that it had already been known for sometime that Antigen Spread(Neo Antigen) was occurring.
So a Dendritic cell vaccine can cause antigen spread and a second generation( targeting theoretically all available tumor antigens via lysate instead of preloading 1 or 5 pre selected antigens) would likely have a greater opportunity of 1. being more successful initially, 2. picking up neo antigens and 3. developing more robust protective memory.
Adam is a hack and proves it with his own words. A biotech analyst should know about Antigen/Epitope spread. Of course he probably does but it doesn't fit his narrative.
P.S. One of the things I got a chuckle out of Youtube video was that LL also has a Political Science degree.
His Tweets to Rago below just about proves his ineptness.
"Dcvax is not a 2nd generation dendritic cell vaccine. It’s way older. Also, it doesn’t target neoantigens, certainly not as currently defined.
Hi Carlo — DCVax is old. It belongs to the first class of “dumb” cancer vaccines, all of which failed (Provenge excepted*). If neoantigens are your thing, I suggest the new crop of cancer vaccine startups. Look at "How many of the previous cancer vaccine trials failed because they did not look at the hazard ratio beyond the median?
He even references Provenge to make his point which actually makes Rago's point if he knew anything about the biology he claims to be an expert on. Provenge showed neoantigens years ago.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876693/
we evaluated humoral antigen spread after sipuleucel-T treatment in patients with metastatic castration-resistant prostate cancer. In addition, we validated a subset of these serum immunoglobulin G responses in patients from the ProACT (Prostate Active Cellular Therapy) study. We presented our results at the 2014 American Society of Clinical Oncology Genitourinary Cancers Symposium. We found that 38% of the patients given sipuleucel-T made antibodies to ERAS, 27% made antibodies to KLK2, and 27% made antibodies to KRAS. It was very clear that this antigen spread occurred only in the patients who got vaccinated—it did not occur in any of the control patients.
So in 2014 they stated that it had already been known for sometime that Antigen Spread(Neo Antigen) was occurring.
So a Dendritic cell vaccine can cause antigen spread and a second generation( targeting theoretically all available tumor antigens via lysate instead of preloading 1 or 5 pre selected antigens) would likely have a greater opportunity of 1. being more successful initially, 2. picking up neo antigens and 3. developing more robust protective memory.
Adam is a hack and proves it with his own words. A biotech analyst should know about Antigen/Epitope spread. Of course he probably does but it doesn't fit his narrative.
P.S. One of the things I got a chuckle out of Youtube video was that LL also has a Political Science degree.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
